^
Association details:
| Biomarker: | KIF5B-RET fusion + MET amplification |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) + Gavreto (pralsetinib) (RET inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Pralsetinib and Sequential MET Inhibitors to Overcome MET Amplification Resistance in a Patient With a RET Fusion Driven Lung Cancer – Case Report
Published date:
08/19/2022
Excerpt:
We report here the first case of a patient who developed a MET amplification as an initial mechanism of acquired resistance to pralsetinib for an advanced KIF5B-RET driven lung adenocarcinoma, successfully treated with a combination of pralsetinib and crizotinib then capmatinib due to an isolated cerebral progression.
DOI:
https://doi.org/10.1016/j.cllc.2022.08.010
